”We're making a significant number of new statements during DCAT Week in New York,”said Frank,describing the accompanying press releases as a”firework display of activity”that's sending”important updates and information to both our customers and to the wider pharmaceutical community.”With a focus on the key issue of pharmaceutical packaging capacity,”we made a very clear and strong statement that we are going to invest US$1 billion in the business during the next couple of years,up to and including 2025,”notes Frank.”Even better news is that the first $300 million is already on its way,”he adds.Giving a little more detail,Frank explains:”We're investing heavily in the tubular part of the business to overcome our current capacity constraint hurdle;we're also creating a new glass tubing production facility in China,as well as financing additional tanks and infrastructure in India.At the same time,we're committing to the construction of a new production facility for SCHOTT TOPPAC ready-to-use polymer syringes and customised container solutions at the SCHOTT site in Mullheim,Germany,as well as increased polymer production capacity in St Gallen,Switzerland.”
展开▼
